Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | KDM4B | O94953 | 1/20 | 0.36 |
| ▸ | KDM5C | P41229 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12234339 | 0.85 | NPSR1 (0.44) | KDM4EKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL16178137 | 0.81 | LMNA (0.36) | KDM4EKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL27572710 | 0.79 | KDM4E (0.44) | KDM4EKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL20241455 | 0.76 | KDM4E (0.41) | KDM4EKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL16774583 | 0.75 | KDM4E (0.40) | KDM4EKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL11354719 | 0.74 | KDM4E (0.42) | KDM4EKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL3161028 | 0.72 | KDM4E (0.41) | KDM4EKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL16287666 | 0.71 | KDM4E (0.40) | KDM4EKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL7393970 | 0.69 | KDM4E (0.38) | KDM4EKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL27669717 | 0.67 | KDM4E (0.36) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014170793-A1 | SULFONAMIDES FOR THE TREATMENT OF GOUT | PFIZER LIMITED (GB) | 2014-10-23 | — | — | WO | disclosed |
| US-20140315933-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315933-A1 | CHEMICAL COMPOUNDS | SULT2A1, SULT1A1, SULT1E1 | KDM4E 3595/4885KDM4A 3150/4885KDM4B 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.